Table 2 Baseline characteristics of patients in updated forms in 2013 (PoPH and I/H-PAH)
From: The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan
PoPH | I/H-PAH | p value | |
|---|---|---|---|
Number | 46 | 730 | |
Sex (F/M) | 26/20 | 492/238 | 0.1365 |
Age (years) | 52.9 ± 17.5 | 52.4 ± 20.0 | 0.8742 |
Age of onset (years) | 45.4 ± 20.8 | 44.1 ± 22.4 | 0.7484 |
6-min walk test | |||
6MWD (m) | 382.8 ± 134.0 | 379.5 ± 136.2 | 0.9255 |
Lowest SpO2 (%) | 92.8 ± 4.2 | 91.1 ± 6.6 | 0.2469 |
Blood exam | |||
BNP (pg/ml) | 104.2 ± 280.8 | 127.0 ± 239.8 | 0.5590 |
UA (mg/dl) | 6.0 ± 2.1 | 5.9 ± 1.9 | 0.7175 |
TRPG (mmHg) | 48.8 ± 21.6 | 55.8 ± 24.9 | 0.0869 |
History of right heart failure (±) | 19/27 | 397/327 | 0.0746 |
NYHA (1/2/3/4) | 8/27/10/0 | 51/420/211/35 | |
Modern PAH therapy (±) (%) | 41/5 [89] | 615/115 [84] | 0.3535 |
IV PGI2 (±) (%) | 1/45 [2] | 148/582 [20] | 0.0003 |
ERA (±) (%) | 24/22 [52] | 503/227 [69] | 0.0221 |
PDE5i (±) (%) | 34/12 [74] | 448/282 [61] | 0.0811 |
Combination therapy (±) [%] | 18/28 [39] | 393/337 [54] | 0.0524 |